Structure Therapeutics
701 Gateway Blvd.
South San Francisco
CA
94080
United States
Tel: 415-503-7483
Website: https://structuretx.com/
Email: info@shoutipharma.com
30 articles about Structure Therapeutics
-
Structure Therapeutics to Present at Leerink Partners Global Biopharma Conference
3/8/2024
Structure Therapeutics Inc. (NASDAQ: GPCR) today announced that Raymond Stevens, Ph.D., the Company’s Founder and Chief Executive Officer, will participate in a fireside chat at the Leerink Partners Global Biopharma Conference on Wednesday, March 13, 2024, at 8:00 AM ET in Miami, Florida.
-
Structure Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Highlights
3/8/2024
Structure Therapeutics Inc. today reported financial results for the fourth quarter and full year ended December 31, 2023, and highlighted recent corporate achievements.
-
A GLP-1-based drug from Structure Therapeutics shows clinical promise but not enough for some on Wall Street.
-
Structure Therapeutics Provides Comprehensive GSBR-1290 Program Update Including Clinically Meaningful Proof-of-Concept Data From Phase 2a Clinical Study
12/18/2023
Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today provided a comprehensive development program update for its highly selective oral GLP-1 receptor agonist, GSBR-1290.
-
Structure Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights
11/14/2023
Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today reported financial results for the third quarter ended September 30, 2023, and highlighted recent corporate achievements.
-
Shares of the biotech startup jumped as much as 70% on Friday after the company reported promising early-stage results for a four-week trial that included only 24 patients.
-
Structure Therapeutics Announces Positive Results from Phase 1b Clinical Study of Oral GLP-1 Receptor Agonist GSBR-1290 and Provides Program Update
9/29/2023
Structure Therapeutics Inc. announced positive results from the Phase 1b multiple ascending dose study of its highly selective oral GLP-1 receptor agonist, GSBR-1290, in healthy overweight or obese individuals.
-
Structure Therapeutics Announces $300 Million Private Placement Equity Financing
9/29/2023
Structure Therapeutics Inc. announced it has entered into a share purchase agreement for the sale of 21,617,295 ordinary shares and 2,401,920 newly designated non-voting ordinary shares at $12.49 per share through a private placement financing.
-
Structure Therapeutics Reports Second Quarter 2023 Financial Results and Recent Highlights
8/10/2023
Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today reported financial results for the second quarter June 30, 2023, and highlighted recent corporate achievements.
-
Structure Therapeutics Appoints Ted W. Love, M.D., to Board of Directors
8/3/2023
Structure Therapeutics Inc., a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and pulmonary diseases, announced that it has appointed Ted W. Love, M.D., to its Board of Directors.
-
7 Life Science IPOs in 2023
7/12/2023
A handful of biotechs and pharma companies have posted sizable IPOs in 2023, despite a tight economy. Still, the numbers are way down from last year. -
Structure Therapeutics Announces Poster Presentations of its Oral GLP-1 Receptor Agonist GSBR-1290 at the American Diabetes Association 83rd Scientific Sessions
6/7/2023
Structure Therapeutics Inc. today announced that clinical and preclinical data from its oral GLP-1 receptor agonist GSBR-1290 program will be presented at the upcoming American Diabetes Association (ADA) 83rd Scientific Sessions taking place June 23-26, 2023, in San Diego.
-
Structure Therapeutics to Present at Jefferies 2023 Healthcare Conference
5/31/2023
Structure Therapeutics Inc. announced that Raymond Stevens, Ph.D., the Company’s Founder and Chief Executive Officer, will present at the Jefferies Healthcare Conference on Thursday, June 8, 2023, at 9:30 AM ET in New York.
-
Structure Therapeutics Initiates Phase 2a Study of Oral GLP-1 agonist GSBR-1290 for the Treatment of Type 2 Diabetes and Obesity
5/25/2023
Structure Therapeutics Inc. announced that it has dosed the first patient in its Phase 2a study of its highly selective oral GLP-1 agonist GSBR-1290 in adults who are overweight or obese and otherwise healthy, and in adults with type 2 diabetes mellitus who are overweight or obese.
-
Structure Therapeutics Announces Poster Presentations at the American Thoracic Society International Conference
5/18/2023
Structure Therapeutics Inc. announced that the Company will present three scientific posters at the upcoming 2023 American Thoracic Society International Conference taking place May 19-24, 2023, in Washington, DC.
-
Structure Therapeutics Reports First Quarter 2023 Financial Results and Recent Highlights
5/11/2023
Structure Therapeutics Inc. reported financial results for the first quarter ended March 31, 2023, and highlighted recent corporate achievements.
-
Structure Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights
3/30/2023
Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and pulmonary diseases, today reported financial results for the fourth quarter and year ended December 31, 2022, and highlighted recent corporate achievements.
-
Structure Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional American Depositary Shares
2/7/2023
Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and pulmonary diseases, today announced the closing of its previously announced upsized initial public offering of 12,351,000 American depositary shares (ADSs).
-
Structure Therapeutics expects to bring in $161.1 million from an upsized IPO, announced Friday.
-
Structure Therapeutics Announces Pricing of Upsized Initial Public Offering
2/3/2023
Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and pulmonary diseases, today announced the pricing of its upsized initial public offering of 10,740,000 American depositary shares (ADSs), each representing three ordinary shares, at a public offering price of $15.00 per ADS.